A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
- Conditions
- Narcolepsy Type 1Narcolepsy Type 2Idiopathic Hypersomnia
- Interventions
- Drug: Placebo
- Registration Number
- NCT06752668
- Lead Sponsor
- Centessa Pharmaceuticals (UK) Limited
- Brief Summary
Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.
While all conditions result in feeling sleepy, there are some differences in other common symptoms:
* NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.
* NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.
* IH: People with IH feel tired during the day, even after sleeping a lot at night. They may sleep for long periods, take long naps, and find it hard to wake up.
Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. ORX750 is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable ORX750 is in NT1, NT2, and IH, and learn about what the drug does to the body. Another goal of the study is to see if ORX750 can help people with NT1, NT2, and IH feel less sleepy and make other symptoms better.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 78
- 18-65 years of age
- BMI ≥17 and ≤37 kg/m2
- Meets the diagnostic criteria of Narcolepsy Type 1 (NT1), Type 2 (NT2) or Idiopathic Hypersomnia (IH) according to ICSD-3-TR criteria
- Is willing and able to discontinue all medications used for the treatment of narcolepsy or idiopathic hypersomnia
- Is willing and able to adhere to additional protocol requirements
- A medical disorder other than NT1, NT2, or IH that is associated with excessive daytime sleepiness (EDS).
- Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological or psychiatric disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Narcolepsy Type 1: ORX750 and Placebo ORX750 - Narcolepsy Type 1: ORX750 and Placebo Placebo - Narcolepsy Type 2: ORX750 and Placebo Placebo - Idiopathic Hypersomnia: ORX750 and Placebo Placebo - Idiopathic Hypersomnia: ORX750 and Placebo ORX750 - Narcolepsy Type 2: ORX750 and Placebo ORX750 -
- Primary Outcome Measures
Name Time Method Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Up to Day 49 Number of Participants With Abnormal Changes From Baseline in Laboratory Tests Up to Day 49 Number of Participants With Abnormal Change From Baseline in Vital Signs Up to Day 49 Number of Participants With Abnormal Change From Baseline in Electrocardiograms (ECG) Up to Day 49 Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) Up to Day 49
- Secondary Outcome Measures
Name Time Method Cmax: Maximum Observed Plasma Concentration for ORX750 Day 1 Tmax: Time of Maximum Concentration for ORX750 Days 1, 14 and 28 AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for ORX750 Day 1 Cmax,ss: Maximum Observed Concentration at Steady State for ORX750 Days 14 and 28 AUCτ: Area Under the Concentration-time Curve During a Dosing Interval at Steady State for ORX750 Days 14 and 28 Mean sleep latency (average of the first 4 trials) in the Maintenance of Wakefulness Test (MWT) for ORX750 versus placebo. Baseline up to Day 42 Mean sleep latency is determined by averaging the time to falling asleep across trials
Change From Baseline in Epworth Sleepiness Scale (ESS) Baseline up to Day 41
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (18)
Newton, Massachusetts
🇺🇸Newton, Massachusetts, United States
Scottsdale, Arizona
🇺🇸Scottsdale, Arizona, United States
Long Beach, California
🇺🇸Long Beach, California, United States
Santa Ana, California
🇺🇸Santa Ana, California, United States
Sterling Heights, Michigan
🇺🇸Sterling Heights, Michigan, United States
North Charleston, South Carolina
🇺🇸North Charleston, South Carolina, United States
Austin, Texas
🇺🇸Austin, Texas, United States
Chandler, Arizona
🇺🇸Chandler, Arizona, United States
Miami, Florida
🇺🇸Miami, Florida, United States
Winter Park, Florida
🇺🇸Winter Park, Florida, United States
Atlanta, Georgia
🇺🇸Atlanta, Georgia, United States
Henderson, Nevada
🇺🇸Henderson, Nevada, United States
Denver, North Carolina
🇺🇸Denver, North Carolina, United States
Huntersville, North Carolina
🇺🇸Huntersville, North Carolina, United States
Cincinnati, Ohio
🇺🇸Cincinnati, Ohio, United States
Columbia, South Carolina
🇺🇸Columbia, South Carolina, United States
San Antonio, Texas
🇺🇸San Antonio, Texas, United States
Toronto, Ontario
🇨🇦Toronto, Ontario, Canada